XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Company Operations by Product
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Company Operations by Product
Company Operations by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended March 31,
Revenues by Product:
 
2018
 
2017
 
 
 
 
 
Bloxiverz
 
$
7,491

 
$
13,902

Vazculep
 
12,961

 
10,179

Akovaz
 
10,217

 
25,638

Noctiva
 
666

 

Other
 
1,826

 
2,038

Total product sales
 
33,161

 
51,757

License revenue
 
132

 
750

Total revenues
 
$
33,293

 
$
52,507